Mounjaro (tirzepatide injection)
FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus; consult the current product label for complete use and safety information.
Current sourceTirzepatide
What approved tirzepatide products and major human trials actually establish
Tirzepatide is a prescription GIP and GLP-1 receptor agonist sold in FDA-approved products with different indications. Mounjaro is approved for specified adults with type 2 diabetes; Zepbound is approved for specified chronic weight-management and obstructive-sleep-apnea uses. Those approvals apply to the named products and their current labeling, not automatically to compounded or online products described only as tirzepatide.
Editorial status
This page aggregates regulatory documents and published human research. Its claims, citations, populations, and limitations received an independent editorial evidence check. Last editorial audit: .
It has not been medically reviewed by a clinician. It provides general education, not diagnosis, treatment, dosing instructions, or advice for an individual. Use the product-specific official information and consult a qualified clinician or pharmacist for personal decisions.
Product and regulatory distinctions
A compound name is not one interchangeable set of instructions. Product, formulation, indication, labeling, and jurisdiction matter.
Zepbound (tirzepatide injection)
FDA-approved for specified adults for long-term weight reduction and maintenance, and for moderate-to-severe obstructive sleep apnea in adults with obesity, with the conditions and limitations in the current label.
Current sourceCompounded or online products described as tirzepatide
These are not Mounjaro or Zepbound merely because they use the ingredient name. FDA approval does not transfer to a different formulation, seller, manufacturing process, or product identity.
Current sourceClaim-by-claim evidence map
Each finding is tied to the population and product actually studied. Trial results are not personal predictions.
Tirzepatide reduced body weight in a phase 3 obesity trial involving adults without diabetes.
- Population
- 2,539 adults with obesity, or overweight plus at least one weight-related complication, without diabetes in SURMOUNT-1.
- Finding
- At 72 weeks, mean body-weight change was -15.0%, -19.5%, and -20.9% across the three tirzepatide groups, compared with -3.1% with placebo.
- Limits
- This was a sponsor-funded trial with defined eligibility, lifestyle intervention, dose escalation, and follow-up. Group averages do not predict an individual's result and do not validate non-approved products.
Tirzepatide lowered glycated hemoglobin in adults with type 2 diabetes in SURPASS-2.
- Population
- 1,879 adults with type 2 diabetes in a 40-week, open-label, randomized phase 3 comparison with semaglutide.
- Finding
- Estimated mean HbA1c changes were -2.01, -2.24, and -2.30 percentage points across the tirzepatide groups, versus -1.86 percentage points in the semaglutide group.
- Limits
- The trial compared particular treatment regimens in a defined diabetes population. It does not establish superiority for every outcome, person, formulation, or use outside approved labeling.
Tirzepatide improved apnea-hypopnea index outcomes in adults with obesity and moderate-to-severe obstructive sleep apnea.
- Population
- Adults with obesity and moderate-to-severe obstructive sleep apnea in two 52-week randomized trials, one without baseline positive-airway-pressure therapy and one with it.
- Finding
- Both trials reported larger reductions in apnea-hypopnea index with tirzepatide than placebo; these trials supported FDA approval of Zepbound for the specified population.
- Limits
- The evidence concerns adults meeting the trial and label criteria and does not replace sleep testing, airway assessment, PAP decisions, or individualized care.
Mounjaro and Zepbound are not interchangeable descriptions for every tirzepatide use.
- Population
- FDA-approved U.S. product labeling and indications.
- Finding
- Mounjaro and Zepbound contain tirzepatide but have product-specific approved indications and labeling; the product name and intended use therefore matter.
- Limits
- Approval status and labeling can change. This summary does not reproduce contraindications, warnings, administration instructions, or the Medication Guide.
What this evidence does not answer
- Trial averages do not predict an individual's benefit, adverse effects, treatment duration, or outcome after discontinuation.
- Evidence for FDA-approved Mounjaro or Zepbound cannot establish the identity, purity, sterility, potency, or clinical equivalence of a compounded or online product.
- The summarized trials do not answer every long-term cardiovascular, pancreatic, gallbladder, retinal, pregnancy, or rare-safety question in every population.
- Comparisons among different trials, brands, and active ingredients are not head-to-head evidence unless the study directly randomized those treatments.
Useful information to organize between visits
- The exact product name, labeled indication, and dispensing pharmacy—not only the ingredient name
- Dates taken and any missed or delayed administration, recorded without self-directed changes
- Symptoms with timing, severity, duration, hydration impact, and whether urgent care was needed
- Relevant glucose, weight, sleep, and other clinician-requested measurements in their original units
- All medicines, supplements, procedures, and anesthesia plans to review with the prescriber or pharmacist
Questions to bring to a clinician or pharmacist
- 1.Which tirzepatide product and approved indication apply to my situation?
- 2.Which warnings, contraindications, interactions, and monitoring items in the current label matter for me?
- 3.What should I do about significant symptoms or a missed administration under my product instructions?
- 4.If the product is compounded, what information can the pharmacy provide about its legal basis, formulation, testing, and quality controls?
Primary sources
- Mounjaro prescribing informationU.S. Food and Drug Administration · Published 2025 · Accessed July 12, 2026
- Zepbound prescribing informationU.S. Food and Drug Administration · Published 2024 · Accessed July 12, 2026
- FDA clarifies policies for compounders as national GLP-1 supply begins to stabilizeU.S. Food and Drug Administration · Published 2026 · Accessed July 12, 2026
- Tirzepatide Once Weekly for the Treatment of ObesityThe New England Journal of Medicine via PubMed · Published 2022 · Accessed July 12, 2026
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 DiabetesThe New England Journal of Medicine via PubMed · Published 2021 · Accessed July 12, 2026
- Tirzepatide for the Treatment of Obstructive Sleep Apnea and ObesityThe New England Journal of Medicine via PubMed · Published 2024 · Accessed July 12, 2026
Turn scattered notes into a useful treatment history
Dosi organizes timing, locations, symptoms, reminders, and questions for your next appointment. It does not prescribe or replace your care team.
Start tracking free